NCT04829071 Cognition and Motor Learning Post-stroke
| NCT ID | NCT04829071 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Southern California |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 65 participants |
| Start Date | 2023-01-16 |
| Primary Completion | 2026-08-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 65 participants in total. It began in 2023-01-16 with a primary completion date of 2026-08-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project seeks to determine how post-stroke cognitive impairment moderates motor learning during walking in older adults with chronic stroke and identify brain structural markers that mediate this relationship. The chosen experimental design integrates biomechanical analyses, neuropsychological assessments, and brain imaging techniques to determine the impact of post-stroke cognitive impairment severity on two forms of motor learning (explicit and implicit) and examine the role of the dorsolateral prefrontal cortex in the relationship between cognition and explicit motor learning. Ultimately, this work may lead to the development of a more comprehensive, effective treatment approach to improve walking dysfunction in older adults post-stroke.
Eligibility Criteria
Inclusion Criteria: * Unilateral stroke * Stroke occurred more than 6 months prior * Paresis confined to one side * Independently ambulatory (including the use of assistive devices) * Able to walk for 5 minutes without stopping * Answers no to all general health questions on the PAR-Q+ * Willingness to complete study procedures Exclusion Criteria: * Brainstem or cerebellar stroke * Aphasia (expressive, receptive, or global) * Any major musculoskeletal or non-stroke neurological condition that interferes with the assessment of sensorimotor or cognitive function * Metal in the head (except in the mouth), implanted cranial or thoracic devices that violate MRI safety regulations * Uncontrolled hypertension (\>160/110mmHg) * Concurrent physical therapy * Claustrophobia * Significant cognitive deficit or dementia (\<20 on MoCA) * Inability to give informed consent
Contact & Investigator
Kristan Leech, PT, DPT, PhD
PRINCIPAL INVESTIGATOR
University of Southern California
Frequently Asked Questions
Who can join the NCT04829071 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 85 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04829071 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT04829071 currently recruiting?
Yes, NCT04829071 is actively recruiting participants. Contact the research team at kleech@pt.usc.edu for enrollment information.
Where is the NCT04829071 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT04829071 clinical trial?
NCT04829071 is sponsored by University of Southern California. The principal investigator is Kristan Leech, PT, DPT, PhD at University of Southern California. The trial plans to enroll 65 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.